Structure盘前暴涨41.8% 实验性减肥药临床研究显示可实现11%减重

Core Insights - Structure Therapeutics announced a weight reduction of 11.3% from its obesity treatment candidate in a mid-stage clinical trial [1] - The company's stock surged by 41.8% in pre-market trading following the announcement [1] Company Summary - Structure Therapeutics is a biotechnology company focused on developing treatments for obesity [1] - The positive results from the clinical trial may enhance the company's market position and investor interest [1]